RichardKBoganMD

Critical Care Medicine, Pleural Disease, Sleep Medicine

Medical Officer SleepMed Inc., Associate Clinical Professor USC School of Medicine, Medical University of SC, Charleston, SC Director SleepMed, Inc. and FCCO Chairman of Board, National Sleep Foundation

Join to view full profile

Dr. Bogan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bogan's full profile

Already have an account?

Office
1333 Taylor St
Suite 6B
Columbia, SC 29201
Phone+1 803-251-3093

Education & Training

University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1976 - 1978
University of Alabama Medical CenterChief Residency, Internal Medicine, 1975 - 1976
University of Alabama Medical CenterResidency, Internal Medicine, 1974 - 1975
United States NavyLt. Commander, Medicine , 1972 - 1974
University of Alabama Medical CenterResidency, Internal Medicine, 1971 - 1972
University of Alabama Medical CenterInternship, Internal Medicine, 1970 - 1971
Medical University of South CarolinaClass of 1970

Certifications & Licensure

SC State Medical License 1978 - 2025
GA State Medical License 1972 - 1989
AL State Medical License 1971 - 1985
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea Start of enrollment: 2011 Aug 01
Terminated
Phase 3
Reiterative Development and Evaluation Study of OSA Therapy System Start of enrollment: 2012 Jul 01
Unknown status
CPAP (Continuous Positive Airway Pressure) Study Educational Materials and Usage Feedback to Promote CPAP Adherence Start of enrollment: 2014 Jan 01
Completed
Not Applicable
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Start of enrollment: 2015 Sep 01
Completed
Phase 2
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Start of enrollment: 2017 Mar 14
Completed
Phase 3
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Start of enrollment: 2017 Jan 01
Completed
Phase 2
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy Start of enrollment: 2019 Sep 21
Completed
Phase 2
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy Start of enrollment: 2021 Oct 26
Completed
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Current knowledge on the pathophysiology of idiopathic hypersomnia and potential mechanisms of action for low-sodium oxybate treatment.
Logan D Schneider, Alyssa Cairns, Chad Ruoff, Richard K Bogan
Journal of Clinical Sleep Medicine. 2025-02-06
1 citations
Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical ...
Michael J Thorpy, Clete A Kushida, Richard Bogan, John Winkelman, Maurice M Ohayon
Sleep Medicine. 2024-12-01
Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis ...
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse
Sleep Medicine. 2024-12-01

Press Mentions

Lumryz Reduces Narcolepsy Symptoms, Regardless of Use of Alerting DrugsSeptember 26th, 2024
VIDEO: Lower-Sodium Oxybate Just as Safe as Oxybate for Idiopathic HypersomniaJune 9th, 2022
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (Solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep ApneaMay 9th, 2022
Join now to see all